BMN 111 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Dec 12, 2016 → Oct 30, 2019
NCT ID
NCT03197766About BMN 111 + Placebo
BMN 111 + Placebo is a phase 3 stage product being developed by BioMarin Pharmaceutical for Achondroplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT03197766. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03583697 | Phase 2 | Completed |
| NCT03197766 | Phase 3 | Completed |
Competing Products
20 competing products in Achondroplasia